Bioline RX(BLRX.US)

Last Updated 19:00:00 ET
longbridge loading

BioLineRx starts Phase 1/2a trial of GLIX1 in recurrent glioblastoma

PUBT·
US
BLRX
-2.33%
PUBT·
US
BLRX
-2.33%

BioLineRx and Hemispherian Announce New GLIX1 Data Demonstrating Potent Anti-Tumor Effect in Glioblastoma (GBM) Across Multiple In-Vivo Studies, Including a Temozolomide (TMZ)-Resistant Model with Patient-Derived Xenografts | BLRX Stock News

StockTitan·
US
BLRX
-2.33%
StockTitan·
US
BLRX
-2.33%

12 Health Care Stocks Moving In Monday's After-Market Session

benzinga_article·
US
BLRX
-2.33%
US
NCNA
+0.99%
US
CDT
-20.00%
benzinga_article·
US
BLRX
-2.33%
US
NCNA
+0.99%
US
CDT
-20.00%

BioLineRx shares are trading higher after the company announces that the first patient has been dosed in its Phase 1/2A study of GLIX-1 for glioblastoma and other high-grade gliomas.

benzinga_article·
US
BLRX
-2.33%
US
LBRX
-3.41%
US
SBIO
-0.67%
benzinga_article·
US
BLRX
-2.33%
US
LBRX
-3.41%
US
SBIO
-0.67%

Hemispherian begins Phase I/IIa trial of GLIX1 for GBM

WorldPharmaceuticals·
US
BLRX
-2.33%
WorldPharmaceuticals·
US
BLRX
-2.33%

Hemispherian Initiates Phase 1/2a Clinical Trial of GLIX1 in Glioblastoma | BLRX Stock News

StockTitan·
US
SBIO
-0.67%
US
FBT
+0.62%
US
VHT
+1.22%
StockTitan·
US
SBIO
-0.67%
US
FBT
+0.62%
US
VHT
+1.22%

BLRX: Full year 2025 results

MSN·
US
BLRX
-2.33%
US
FBT
+0.62%
MSN·
US
BLRX
-2.33%
US
FBT
+0.62%

Options Volatility and Implied Earnings Moves Today, March 23, 2026

Tip Ranks·
US
XLV
+1.32%
US
SBIO
-0.67%
US
LAR
-5.59%
Tip Ranks·
US
XLV
+1.32%
US
SBIO
-0.67%
US
LAR
-5.59%

BioLineRx Reports 2025 Financial Results and Provides Corporate Update | BLRX Stock News

StockTitan·
US
BLRX
-2.33%
US
FBT
+0.62%
StockTitan·
US
BLRX
-2.33%
US
FBT
+0.62%
© 2026 Longbridge｜Disclaimer